PTC Therapeutics Inc (PTCT)
39.23
-3.15
(-7.43%)
USD |
NASDAQ |
Nov 15, 16:00
39.24
0.00 (0.00%)
After-Hours: 20:00
PTC Therapeutics Research and Development Expense (TTM): 531.06M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 531.06M |
| June 30, 2024 | 533.86M |
| March 31, 2024 | 587.57M |
| December 31, 2023 | 666.56M |
| September 30, 2023 | 733.90M |
| June 30, 2023 | 735.15M |
| March 31, 2023 | 706.54M |
| December 31, 2022 | 651.50M |
| September 30, 2022 | 612.65M |
| June 30, 2022 | 578.03M |
| March 31, 2022 | 546.25M |
| December 31, 2021 | 540.68M |
| September 30, 2021 | 508.85M |
| June 30, 2021 | 471.01M |
| March 31, 2021 | 522.05M |
| December 31, 2020 | 477.64M |
| September 30, 2020 | 441.46M |
| June 30, 2020 | 411.54M |
| March 31, 2020 | 294.99M |
| December 31, 2019 | 257.45M |
| September 30, 2019 | 229.27M |
| June 30, 2019 | 220.56M |
| March 31, 2019 | 193.19M |
| December 31, 2018 | 171.98M |
| Date | Value |
|---|---|
| September 30, 2018 | 147.57M |
| June 30, 2018 | 123.23M |
| March 31, 2018 | 121.46M |
| December 31, 2017 | 117.46M |
| September 30, 2017 | 114.23M |
| June 30, 2017 | 115.60M |
| March 31, 2017 | 113.60M |
| December 31, 2016 | 117.63M |
| September 30, 2016 | 126.67M |
| June 30, 2016 | 125.91M |
| March 31, 2016 | 125.28M |
| December 31, 2015 | 121.82M |
| September 30, 2015 | 113.64M |
| June 30, 2015 | 101.76M |
| March 31, 2015 | 91.89M |
| December 31, 2014 | 79.84M |
| September 30, 2014 | 67.99M |
| June 30, 2014 | 63.11M |
| March 31, 2014 | 59.51M |
| December 31, 2013 | 54.88M |
| September 30, 2013 | 49.31M |
| June 30, 2013 | 45.89M |
| March 31, 2013 | 43.09M |
| December 31, 2012 | 46.14M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
257.45M
Minimum
Dec 2019
735.15M
Maximum
Jun 2023
540.44M
Average
537.27M
Median
Research and Development Expense (TTM) Benchmarks
| ClearPoint Neuro Inc | 11.71M |
| Pfizer Inc | 10.60B |
| Vertex Pharmaceuticals Inc | 3.456B |
| BridgeBio Pharma Inc | 506.34M |
| Cassava Sciences Inc | 67.84M |